Patents by Inventor Curtis R. Brandt
Curtis R. Brandt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9221874Abstract: The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.Type: GrantFiled: January 24, 2012Date of Patent: December 29, 2015Assignee: Wisconsin Alumni Research FoundationInventors: Stacey L. Schultz-Cherry, Curtis R. Brandt, Jeremy C. Jones
-
Patent number: 9198965Abstract: The present disclosure generally relates to peptides having adjuvant properties, vaccines comprising the adjuvant peptides, and their use in prophylaxis or therapy for influenza. More particularly, the invention relates to adjuvant peptides that induce aggregation of influenza virus. The peptides can be included in influenza vaccines to increase the immune response to the vaccine.Type: GrantFiled: June 15, 2009Date of Patent: December 1, 2015Assignee: Wisconsin Alumni Research FoundationInventors: Stacey L. Schultz-Cherry, Curtis R. Brandt, Jeremy C. Jones
-
Patent number: 8748565Abstract: This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.Type: GrantFiled: April 2, 2008Date of Patent: June 10, 2014Assignee: Wisconsin Alumni Reseach FoundationInventors: Curtis R. Brandt, Hermann Bultmann
-
Patent number: 8748566Abstract: This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.Type: GrantFiled: November 7, 2008Date of Patent: June 10, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Curtis R. Brandt, Hermann Bultmann
-
Publication number: 20130190228Abstract: The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.Type: ApplicationFiled: January 24, 2012Publication date: July 25, 2013Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Stacey L. Schultz-Cherry, Curtis R. Brandt, Jeremy C. Jones
-
Publication number: 20120157376Abstract: This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.Type: ApplicationFiled: April 2, 2008Publication date: June 21, 2012Inventors: Curtis R. Brandt, Hermann Bultmann
-
Patent number: 8129499Abstract: The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.Type: GrantFiled: June 15, 2009Date of Patent: March 6, 2012Assignee: Wisconsin Alumni Research FoundationInventors: Stacey L. Schultz-Cherry, Curtis R. Brandt, Jeremy C. Jones
-
Publication number: 20100041604Abstract: The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.Type: ApplicationFiled: June 15, 2009Publication date: February 18, 2010Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Stacey L. Schultz-Cherry, Curtis R. Brandt, Jeremy C. Jones
-
Publication number: 20100040642Abstract: The present disclosure generally relates to peptides having adjuvant properties, vaccines comprising the adjuvant peptides, and their use in prophylaxis or therapy for influenza. More particularly, the invention relates to adjuvant peptides that induce aggregation of influenza virus. The peptides can be included in influenza vaccines to increase the immune response to the vaccine.Type: ApplicationFiled: June 15, 2009Publication date: February 18, 2010Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Stacey L. Schultz-Cherry, Curtis R. Brandt, Jeremy C. Jones
-
Publication number: 20090253624Abstract: This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.Type: ApplicationFiled: November 7, 2008Publication date: October 8, 2009Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Curtis R. Brandt, Hermann Bultmann
-
Patent number: 7432045Abstract: This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.Type: GrantFiled: December 1, 2004Date of Patent: October 7, 2008Assignee: Wisconsin Alumni Research FoundationInventors: Curtis R. Brandt, Hermann Bultmann
-
Patent number: 7371809Abstract: This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.Type: GrantFiled: February 6, 2001Date of Patent: May 13, 2008Assignee: Wisconsin Alumni Research FoundationInventors: Curtis R. Brandt, Hermann Bultmann
-
Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
Patent number: 6106826Abstract: Degenerative diseases of the retina are a leading cause of vision loss in the United States, affecting approximately two million people each year. The replacement of a defective gene by gene therapy provides one approach for treating individuals having ocular neuronal degeneration where the defective gene has been identified. Several factors, however, suggest that the replacement of a specific gene in a patient might not be effective. For example, many of the conditions are autosomal dominant, and placing a normal copy of the gene into the cells would not correct the defect. As an alternative, replication competent, avirulent, ribonuclease reductase deficient Herpes simplex virus can provide the means to deliver therapeutic polypeptides in a continuous manner to affected cells. Such therapeutic polypeptides include growth factors, neurotrophins and cytokines.Type: GrantFiled: December 17, 1997Date of Patent: August 22, 2000Assignee: Wisconsin Alumni Research FoundationInventors: Curtis R. Brandt, Ronald E. Kalil, Seema Agarwala -
Patent number: 5714464Abstract: A substantially pure compound extracted from the mushroom Rozites caperata is disclosed. The compound disclosed is SEQ ID NO:1, a twelve amino acid peptide, covalently linked by the epsilon amino group of a carboxy terminal lysine to the carboxyl terminus of SEQ ID NO:2, or a pharmaceutically acceptable nontoxic salt of the compound. The disclosed compound inhibits replication of viruses having lipid bilayer envelopes. Also disclosed is a method for inhibiting replication of viruses having lipid bilayer envelopes. According to the method, such viruses can be inhibited by administering an effective amount of a substantially pure compound, which is SEQ ID NO:1 covalently to SEQ ID NO:2, or a pharmaceutically acceptable nontoxic salt of the compound.Type: GrantFiled: August 9, 1995Date of Patent: February 3, 1998Assignee: Wisconsin Alumni Research FoundationInventors: Frank Piraino, Curtis R. Brandt